ATE81977T1 - Verfahren zur behandlung von maennlicher sexueller dysfunktion. - Google Patents

Verfahren zur behandlung von maennlicher sexueller dysfunktion.

Info

Publication number
ATE81977T1
ATE81977T1 AT87306224T AT87306224T ATE81977T1 AT E81977 T1 ATE81977 T1 AT E81977T1 AT 87306224 T AT87306224 T AT 87306224T AT 87306224 T AT87306224 T AT 87306224T AT E81977 T1 ATE81977 T1 AT E81977T1
Authority
AT
Austria
Prior art keywords
sexual dysfunction
male sexual
treatment
dhc
compositions
Prior art date
Application number
AT87306224T
Other languages
English (en)
Inventor
Wesley R Anderson
Nicholas S Bodor
James W Simpkins
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Application granted granted Critical
Publication of ATE81977T1 publication Critical patent/ATE81977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT87306224T 1986-08-04 1987-07-14 Verfahren zur behandlung von maennlicher sexueller dysfunktion. ATE81977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/892,861 US4863911A (en) 1986-08-04 1986-08-04 Method for treating male sexual dysfunction
EP87306224A EP0256668B1 (de) 1986-08-04 1987-07-14 Verfahren zur Behandlung von männlicher sexueller Dysfunktion

Publications (1)

Publication Number Publication Date
ATE81977T1 true ATE81977T1 (de) 1992-11-15

Family

ID=25400626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306224T ATE81977T1 (de) 1986-08-04 1987-07-14 Verfahren zur behandlung von maennlicher sexueller dysfunktion.

Country Status (8)

Country Link
US (1) US4863911A (de)
EP (1) EP0256668B1 (de)
JP (1) JP2646568B2 (de)
AT (1) ATE81977T1 (de)
AU (1) AU603368B2 (de)
CA (1) CA1300020C (de)
DE (1) DE3782468T2 (de)
IE (1) IE61350B1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883087A (en) * 1991-01-07 1999-03-16 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5925774A (en) 1991-01-07 1999-07-20 Pherin Corporation Estrenes for inducing hypothalamic effects
US5969168A (en) * 1991-01-07 1999-10-19 Pherin Corporation Androstanes for inducing hypothalamic effects
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
DE4319096C1 (de) * 1993-06-08 1994-09-08 Kuhl Herbert Prof Dr Phil Nat Hormonales Mittel zur Vorbeugung und Behandlung arterieller Erkrankungen beim Mann
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
ES2091724B1 (es) * 1995-04-07 1997-06-01 Ropero Wermenlinger Luis Nueva locion potenciadora de la capacidad sexual en el hombre, procedimiento para su preparacion y sus aplicaciones.
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
CN102114024B (zh) * 2009-12-30 2012-05-30 宋杰 预防月经期偏头痛的复方雌谷胶囊

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
US4210644A (en) * 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
DE3382795T2 (de) * 1982-05-18 1996-02-15 University Of Florida, Gainesville, Fla. Gehirnspezifische arzneimittelabgabe.
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control

Also Published As

Publication number Publication date
US4863911A (en) 1989-09-05
AU603368B2 (en) 1990-11-15
JP2646568B2 (ja) 1997-08-27
AU7630887A (en) 1988-02-11
JPS6399095A (ja) 1988-04-30
IE871749L (en) 1988-02-04
EP0256668A3 (en) 1989-10-04
CA1300020C (en) 1992-05-05
DE3782468T2 (de) 1993-03-18
IE61350B1 (en) 1994-11-02
EP0256668A2 (de) 1988-02-24
EP0256668B1 (de) 1992-11-04
DE3782468D1 (de) 1992-12-10

Similar Documents

Publication Publication Date Title
DE3782468D1 (de) Verfahren zur behandlung von maennlicher sexueller dysfunktion.
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
AU2003283282A8 (en) Tubulysins, method for producing the same and tubulysin preparations
IL133434A (en) Use of polyamine polymers in the preparation of medicaments for removing bile salts and for treating hypercholesterolemia
AU9164791A (en) Method and compositions for treatment of sexual impotence
FI961098A0 (fi) Menetelmä progestogeniä ja estrogeniä sisältävän korvikkeen valmistamiseksi
LV12572A (en) Method for introducing a 1,2 double bond into 4-azasteroids and crystalline phroscor(r) and pharmaceutical compositions thereof
AU609664B1 (en) A method of treating premature ejaculation using sertraline
IL98258A0 (en) Composition for treating impotence containing doxazosin,amlodipine,or u.k.52,046
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
FI904035A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia 4-substituoituja 17 -(syklopropyyliamino)androst-5-eenijohdannaisia, jotka ovat hyödyllisiä C17-20-lyaasi-inhibiittoreina
PL300327A1 (en) Substituted cycolohexane derivatives, method of obtaining them and application of these compounds in treating diseases
EP0197488A3 (de) 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung, diese enthaltende Arzneimittel und ihre Verwendung
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
ES2006619A6 (es) Un metodo para preparar derivados de piridil-y pirimidil-piperazinas.
EP0220844A3 (de) Verwendung von Östrogen-dihydropyridinverbindungen zur Gewichtsreglung
EP0354568A3 (de) Catechol-Derivate
GR3034155T3 (en) Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
ATE71099T1 (de) Calcium-4,6-dioxo-4h-pyrano(3,2-g>-chinolin-2,8 dicarboxylat-derivat, verfahren zu seiner herstellung und dieses enthaltende zusammensetzungen.
MX9804828A (es) Benzotiazolona etanaminas biologicamente activas.
IE883793L (en) Method of inhibiting human immunodeficiency virus
ES2140668T3 (es) Intercaladores bifuncionales derivados de acridona que se utilizan como agentes quimioterapeuticos.
IT9086204A0 (it) Metodo per la cura dell'impotenza erettiva maschile